Why Vertex Pharmaceuticals stock moves
Vertex Pharmaceuticals rose slightly without a company-news explanation.
Written after the close on ·
Why today
16,413 news analyzed todayVertex Pharmaceuticals rose slightly without a company-news explanation.
The stock moved more than the S&P 500, which was roughly flat, while its healthcare sector was also roughly unchanged.
The move was an ordinary one for Vertex, within its usual daily range.
Over the last five trading days, the stock fell slightly, in line with a sharp fall in the S&P 500.
News from earlier this week included the third-quarter results, where revenue rose 12% and the full-year revenue forecast was raised.
Today's move of +0.85% was 0.8 times a normal day's 1.1%. S&P 500 moved +0.31% on the same day.
Vertex Pharmaceuticals +0.85%S&P 500 +0.31%A little stronger than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Vertex Pharmaceuticals.
Vertex Pharmaceuticals earned more than expected in 3 out of 8 reports.
For comparison, about 82% of reports from US companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 3 out of 8 reports with a measured move, against about 55% of reports from US companies.
Ratings
Price targets
Latest price $547.09
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expected$
Next reported quarter: expected earnings per share of $4.78 (February 11). For the current fiscal year, expected earnings per share changed from $19.04 three months ago to $18.12 now. 2026 estimate: $18.12. 2027 estimate: $19.92.
Has the share price followed the business?
Price and earnings moved in the same direction: 3 out of 3 years. Across US companies, that happens in about 65% of years. In 2025, the price changed +13% and earnings per share went from -$2.08 to $15.32.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.$B
Assets, liabilities and market cap
AssetsLiabilitiesMarket cap$B
Price and earnings moved in the same direction: 3 out of 3 years.Market cap (Now): $138.7BRevenue 2025: $12.0B
What the key figures say about Vertex Pharmaceuticals
The figures connect what Vertex Pharmaceuticals earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -$2.08–$15.32. Peers: Moderna -$7.04, Regeneron Pharmaceuticals $45.24, Genmab 75.25 DKK. 2026 estimate: $18.12 ($17.75–$19.17). 2027 estimate: $19.92 ($17.97–$21.87).
What the company sold during the year.
2022–2025: $8.9B–$12.0B. Peers: Moderna $2.5B, Regeneron Pharmaceuticals $16.9B, Genmab $4.3B. 2026 estimate: $13.3B ($13.2B–$13.4B). 2027 estimate: $14.6B ($14.0B–$15.2B).
The percentage of revenue left after the costs of running the business.
2022–2025: −2.1%–47.6%. Peers: Moderna −150.2%, Regeneron Pharmaceuticals 30.4%, Genmab 30.6%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −3.3%–23.9%. Peers: Moderna −34.5%, Regeneron Pharmaceuticals 14.9%, Genmab 12.1%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 22.5–29.6. Peers: Regeneron Pharmaceuticals 20.0, Genmab 46.9. 2026 estimate: 30.2. 2027 estimate: 27.5.
What investors pay for each unit the company sells.
2022–2025: 8.31–10.62. Peers: Moderna 40.73, Regeneron Pharmaceuticals 5.54. 2026 estimate: 10.47. 2027 estimate: 9.47.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -8.99–-0.94. Peers: Regeneron Pharmaceuticals -1.17, Genmab 2.45.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 5.33–6.31. Peers: Moderna 11.58, Regeneron Pharmaceuticals 2.71.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 15.0–355.1.
Cash left after investments, divided by the number of shares.
2022–2025: -$3.81–$15.27. Peers: Moderna -$3.07, Regeneron Pharmaceuticals $35.07, Genmab $13.71.
The percentage of assets financed by shareholders’ equity.
2022–2025: 72.8%–77.3%.
What to watch next, and why
The earnings report shows how Vertex Pharmaceuticals's revenue and profit have changed.
- Earnings report
The earnings report shows how Vertex Pharmaceuticals's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Vertex Pharmaceuticals usually moved about 3.0%. On a normal day it moves 1.1%.
−4.05% Why? +1.70% −1.28% +5.69%
$10,000 in Vertex Pharmaceuticals bought on November 7, 2016 is worth $65,700 today, with dividends reinvested.
The same amount in S&P 500 with dividends would have become $40,400.
What would $10,000 in Vertex Pharmaceuticals be worth today? →
What would $10,000 in Vertex Pharmaceuticals be worth today?
$65,700
with dividends reinvested, bought on November 7, 2016. The same amount in S&P 500 with dividends would have become $40,400.
At worst it was worth $8,650 (December 22, 2016).
The five biggest days of the journey
· +20.8% · the whole market rose 0.5% the same day
· −20.7% · the whole market fell 0.2% the same day
· −20.6% · the whole market fell 0.5% the same day · report day
· +20.5% · the whole market rose 0.1% the same day
· +15.2% · the whole market rose 0.1% the same day
Earlier days
−1.19% market −4.41% Vertex Pharmaceuticals fell without a company-news explanation. Read →
Vertex Pharmaceuticals fell without a company-news explanation.
Vertex Pharmaceuticals fell clearly in the last session, while the S&P 500 fell very sharply, so it held up better than the market.
Over the last five trading days the stock was roughly unchanged, while the market fell very sharply.
Trading volume was about twice a normal session, so heavy selling drove the drop.
The latest close is near its one-year high, so the stock is still well above last year's low.
+3.44% market +1.65% Vertex Pharmaceuticals rose on its strong third-quarter results and raised guidance. Read →
Vertex Pharmaceuticals rose on its strong third-quarter results and raised guidance.
Vertex Pharmaceuticals moved in line with its sector and more than the S&P 500, which rose sharply too.
The rise came after the earnings release, which reported revenue up 12% and raised full-year revenue guidance, the outlook for sales.
Analysts raised price targets, the share prices they see as fair, after the report.
Over the last five trading days the stock rose clearly while the S&P 500 fell slightly, a big move for the stock.
−4.05% market +0.30% Vertex Pharmaceuticals fell after its quarterly earnings release. Read →
Vertex Pharmaceuticals fell after its quarterly earnings release.
The stock moved against the S&P 500, which rose slightly that day.
Its sector ETF fell only slightly, so the drop was much larger than its peers.
Earnings came in about in line with expectations, while revenue rose 12% and full-year revenue guidance was raised.
The move was about four times a normal day and happened on heavy trading volume.
−1.03% market −0.48% Vertex Pharmaceuticals fell slightly without a company-news explanation. Read →
Vertex Pharmaceuticals fell slightly without a company-news explanation.
Over the last five trading days the stock rose sharply, a very big move, while the S&P 500 fell clearly.
Last session the S&P 500 also fell slightly, so the stock moved more than the market.
Trading volume was well above its usual level, about twice a normal session.
The stock is near its highest close of the past year, and it is well above its lowest.
+3.50% market −1.77% Vertex Pharmaceuticals rose sharply, reaching a record high. Read →
Vertex Pharmaceuticals rose sharply, reaching a record high.
Its rise came on a day the S&P 500 fell sharply, so it moved against the broader market.
Vertex Pharmaceuticals rose more than the healthcare sector, which also gained.
The trading volume was well above its usual level, showing strong interest.
Company news from that day, including a report on why the stock was up and a note that it hit an all-time high, points to investor enthusiasm, though no single event is clearly confirmed as the cause.
−2.10% market −0.52% Vertex Pharmaceuticals fell sharply, moving more than the market. Read →
Vertex Pharmaceuticals fell sharply, moving more than the market.
Over the same day the S&P 500 fell clearly, and the Healthcare sector ETF, a fund tracking the sector, also fell clearly.
The move was a big one, roughly twice a normal five-day stretch for the stock, and it was less about company news than sector and market weakness.
Over the last five trading days the stock rose sharply while the market slipped slightly, so the week went the other way.
Its next earnings report, the company's quarterly results, is due Monday 2 November.
+4.84% market −0.43% Vertex Pharmaceuticals rose sharply over the last five trading days, moving against a slightly weaker S&P 500 market. Read →
Vertex Pharmaceuticals rose sharply over the last five trading days, moving against a slightly weaker S&P 500 market.
The gain was a big move for the company, roughly twice its normal five-day swing.
Analyst Citi kept its buy rating and its price target, the share price it sees as fair, of $585, which supports sentiment.
Director stock grants and board appointments, including Daniel Brennan joining the board, were routine governance news and likely added little.
+2.03% market −1.18% Vertex Pharmaceuticals rose sharply, a big move for its own standards. Read →
Vertex Pharmaceuticals rose sharply, a big move for its own standards.
The S&P 500 fell sharply that day, so Vertex moved against the market.
No company news from the last session clearly explains the rise.
The stock's gain came alongside a strong rise in the healthcare sector, which suggests sector buying helped.
Over the last five trading days, Vertex rose sharply while the S&P 500 fell slightly.
+1.92% market +0.53% Vertex Pharmaceuticals rose clearly, with no company news explaining the move. Read →
Vertex Pharmaceuticals rose clearly, with no company news explaining the move.
The stock outperformed the S&P 500, which also rose clearly, while its healthcare sector fell slightly.
Over the last five trading days, Vertex rose sharply, a big move about twice its normal five-day swing.
Investors may be reacting to recent pipeline data and the strong investor interest in its new drugs.
The next earnings report is due Monday 2 November 2026.
+2.53% market +0.34% Vertex Pharmaceuticals rose sharply, moving more than the market. Read →
Vertex Pharmaceuticals rose sharply, moving more than the market.
The S&P 500 rose only slightly, and the healthcare sector rose very sharply, so the stock moved in line with its sector.
Company news from the last session is limited: a board appointment, a director share-trade filing and a lobbying disclosure, none clearly driving a move this large.
Over the last five trading days the stock rose sharply while the S&P 500 fell clearly, so it moved against the market.
Its next earnings report, the company's quarterly results, is due Monday 2 November 2026.
+2.06% market +0.28% Vertex Pharmaceuticals rose sharply, outpacing a slightly higher S&P 500 and moving in line with a sharply rising healthcare sector. Read →
Vertex Pharmaceuticals rose sharply, outpacing a slightly higher S&P 500 and moving in line with a sharply rising healthcare sector.
The most likely driver is broad sector buying, partly reinforced by company-specific interest: several items from that session highlighted the stock's outperformance and its pipeline, including a report on its cystic fibrosis and hormone-disorder programs.
Over the last five trading days the stock edged up slightly while the market was roughly flat, so the session stood out against a quiet week.
+2.74% market −1.08% Vertex Pharmaceuticals rose very sharply, moving against a sharply falling S&P 500 and in line with a very strongly rising healthcare sector, so it looks like a sector-wide rally plus a company-specific boost. Read →
Vertex Pharmaceuticals rose very sharply, moving against a sharply falling S&P 500 and in line with a very strongly rising healthcare sector, so it looks like a sector-wide rally plus a company-specific boost.
Over the last five trading days the stock fell slightly, in line with the market and against a sharply rising healthcare sector, and the $10 billion acquisition announced the day before the session is a likely reason for the earlier softness.
−4.30% market −0.01% Vertex slips as healthcare stocks weaken. Read →
Vertex slips as healthcare stocks weaken.
Over the last five trading days Vertex Pharmaceuticals fell sharply, moving against a clearly higher healthcare sector and a roughly flat broad market.
Earlier in the period, positive trial data for ALYFTREK in very young cystic fibrosis patients and a regulatory clearance for Casgevy in children aged two and up had lifted the shares, so the recent drop looks like a give-back of those gains.
Watch the third-quarter results and the launch progress of Casgevy, Journavx and Alyftrek.
Learn more · Why do stocks go up and down?